Skip to main content

Articles

Page 1 of 109

  2. In 2022, our team launched the pioneering national proficiency testing (PT) scheme for the pathological diagnosis of breast cancer, rapidly establishing its credibility throughout China. Aiming to continuously...

    Authors: Xuemin Xue, Lei Guo, Changyuan Guo, Liwei Xu, Lin Li, Lin Yang, Xin Wang, Wei Rao, Pei Yuan, Jiali Mu, Jiangtao Li, Bingning Wang, Quan Zhou, Weicheng Xue, Fei Ma, Wenjing Yang…
    Citation: Breast Cancer Research 2024 26:128
    Content type: Research Published on:

  3. Ductal carcinoma in situ (DCIS) is a non-obligate precursor to invasive breast cancer (IBC). Studies have indicated differences in DCIS outcome based on race or ethnicity, but molecular differences have not be...

    Authors: Siri H. Strand, Kathleen E. Houlahan, Vernal Branch, Thomas Lynch, Belén Rivero-Guitiérrez, Bryan Harmon, Fergus Couch, Kristalyn Gallagher, Mark Kilgore, Shi Wei, Angela DeMichele, Tari King, Priscilla McAuliffe, Christina Curtis, Kouros Owzar, Jeffrey R. Marks…
    Citation: Breast Cancer Research 2024 26:127
    Content type: Research Published on:

  4. Aurora kinase A (AURKA) is reported to be overexpressed in breast cancer. In addition to its role in regulating cell cycle and mitosis, studies have reported AURKA involvements in oncogenic signaling in suppressi...

    Authors: L. M. Ingebriktsen, R. O. C. Humlevik, A. A. Svanøe, A. K. M. Sæle, I. Winge, K. Toska, M. B. Kalvenes, B. Davidsen, A. Heie, G. Knutsvik, C. Askeland, I. M. Stefansson, E. A. Hoivik, L. A. Akslen and E. Wik
    Citation: Breast Cancer Research 2024 26:126
    Content type: Research Published on:

  5. In many countries, hormone receptor status assessment of ductal carcinoma in situ (DCIS) is routinely performed, as hormone receptor-positive DCIS patients are eligible for adjuvant anti-hormonal treatment, ai...

    Authors: Mieke R. Van Bockstal, Jelle Wesseling, Ester H. Lips, Marjolein Smidt, Christine Galant and Carolien H. M. van Deurzen
    Citation: Breast Cancer Research 2024 26:125
    Content type: Perspective Published on:

  6. Human epidermal growth factor receptor 2 (HER2)-low breast cancer has emerged as a new subtype of tumor, for which novel antibody–drug conjugates have shown beneficial effects. Assessment of HER2 requires seve...

    Authors: Renan Valieris, Luan Martins, Alexandre Defelicibus, Adriana Passos Bueno, Cynthia Aparecida Bueno de Toledo Osorio, Dirce Carraro, Emmanuel Dias-Neto, Rafael A. Rosales, Jose Marcio Barros de Figueiredo and Israel Tojal da Silva
    Citation: Breast Cancer Research 2024 26:124
    Content type: Research Published on:

  7. Stratipath Breast is a CE-IVD marked artificial intelligence-based solution for prognostic risk stratification of breast cancer patients into high- and low-risk groups, using haematoxylin and eosin (H&E)-stain...

    Authors: Abhinav Sharma, Sandy Kang Lövgren, Kajsa Ledesma Eriksson, Yinxi Wang, Stephanie Robertson, Johan Hartman and Mattias Rantalainen
    Citation: Breast Cancer Research 2024 26:123
    Content type: Research Published on:

  8. A better understanding of ductal carcinoma in situ (DCIS) is urgently needed to identify these preinvasive lesions as distinct clinical entities. Semaphorin 3F (SEMA3F) is a soluble axonal guidance molecule, a...

    Authors: Núria Moragas, Patricia Fernandez-Nogueira, Leire Recalde-Percaz, Jamie L. Inman, Anna López-Plana, Helga Bergholtz, Aleix Noguera-Castells, Pedro J. del Burgo, Xieng Chen, Therese Sorlie, Pere Gascón, Paloma Bragado, Mina Bissell, Neus Carbó and Gemma Fuster
    Citation: Breast Cancer Research 2024 26:122
    Content type: Research Published on:

  9. Accumulating evidence suggests that cardiovascular diseases and breast cancer share a number of common risk factors, however, evidence on the association between cardiovascular health (CVH) and breast cancer i...

    Authors: Yan Zhao, Yang Song, Xiangmin Li and Ayao Guo
    Citation: Breast Cancer Research 2024 26:121
    Content type: Research Published on:

  10. The significance of minimal residual axillary disease, specifically micrometastases, following neoadjuvant systemic therapy (NST) remains largely unexplored. Our study aimed to elucidate the prognostic implica...

    Authors: Janghee Lee, Seho Park, Soong June Bae, Junghwan Ji, Dooreh Kim, Jee Ye Kim, Hyung Seok Park, Sung Gwe Ahn, Seung Il Kim, Byeong-Woo Park and Joon Jeong
    Citation: Breast Cancer Research 2024 26:120
    Content type: Research Published on:

  11. Breast cancer is the most common cancer in women diagnosed in the U.S. and worldwide. Obesity increases breast cancer risk without clear underlying molecular mechanisms. Our studies demonstrate that circulatin...

    Authors: Jiaqing Hao, Rong Jin, Yanmei Yi, Xingshan Jiang, Jianyu Yu, Zhen Xu, Nicholas J. Schnicker, Michael S. Chimenti, Sonia L. Sugg and Bing Li
    Citation: Breast Cancer Research 2024 26:119
    Content type: Research Published on:

  12. Male breast cancer (MaBC) has limited data on genomic alterations. We aimed to comprehensively describe and compare MaBC’s genomics with female breast cancer’s (FBC) across subtypes.

    Authors: Arun Kadamkulam Syriac, Nitish Singh Nandu, Allison Clark, Mehrad Tavallai, Dexter X. Jin, Ethan Sokol, Kimberly McGregor, Jeffrey S. Ross, Natalie Danziger and Jose Pablo Leone
    Citation: Breast Cancer Research 2024 26:118
    Content type: Research Published on:

  13. Diabetes mellitus (DM) affects up to one-third of breast cancer (BC) patients. Patients with co-existing BC and DM (BC-DM) have worsened BC prognosis. Nevertheless, the molecular mechanisms orchestrating BC-DM...

    Authors: Yongyi Huang, Cheng Chen, Yang Liu, Binbin Tan, Qin Xiang, Qianqian Chen, Yiling Wang, Wenhan Yang, Jingsong He, Duanyang Zhou, Yuting Wang, Kaiping Gao, Duo Zheng and Rihong Zhai
    Citation: Breast Cancer Research 2024 26:117
    Content type: Research Published on:

  14. Higher mammographic density (MD), a radiological measure of the proportion of fibroglandular tissue in the breast, and lower terminal duct lobular unit (TDLU) involution, a histological measure of the amount o...

    Authors: Waruiru Mburu, Changyuan Guo, Yuan Tian, Hela Koka, Sheng Fu, Ning Lu, Erni Li, Jing Li, Renata Cora, Ariane Chan, Jennifer L. Guida, Hyuna Sung, Gretchen L. Gierach, Mustapha Abubakar, Kai Yu and Xiaohong R. Yang
    Citation: Breast Cancer Research 2024 26:116
    Content type: Research Published on:

  15. Various histopathological, clinical and imaging parameters have been evaluated to identify a subset of women diagnosed with lesions with uncertain malignant potential (B3 or BIRADS 3/4A lesions) who could safe...

    Authors: Tanjina Kader, Elena Provenzano, Madawa W. Jayawardana, Shona Hendry, Jia-Min Pang, Kenneth Elder, David J. Byrne, Lauren Tjoeka, Helen ML. Frazer, Eloise House, Sureshni I. Jayasinghe, Holly Keane, Anand Murugasu, Neeha Rajan, Islam M. Miligy, Michael Toss…
    Citation: Breast Cancer Research 2024 26:115
    Content type: Research Published on:

  16. The protein Bcl-2, well-known for its anti-apoptotic properties, has been implicated in cancer pathogenesis. Identifying the primary gene responsible for promoting improved cell survival and development has pr...

    Authors: Noor Bahadar, Sher Bahadar, Abdul Sajid, Muqeet Wahid, Ghadir Ali, Abdullah Alghamdi, Hakeem Zada, Tamreez Khan, Shafqat Ullah and Qingjia Sun
    Citation: Breast Cancer Research 2024 26:114
    Content type: Research Published on:

  17. GNA13 (Gα13) is one of two alpha subunit members of the G12/13 family of heterotrimeric G-proteins which mediate signaling downstream of GPCRs. It is known to be essential for embryonic development and vasculogen...

    Authors: Lalitha Vaishnavi Subramanyan, Suhail Ahmed Kabeer Rasheed, Lijin Wang, Sujoy Ghosh, Michelle Shi Ning Ong, Manikandan Lakshmanan, Mei Wang and Patrick J. Casey
    Citation: Breast Cancer Research 2024 26:113
    Content type: Research Published on:

  18. Gene expression profiles in breast tissue biopsies contain information related to chemotherapy efficacy. The promoter profiles in cell-free DNA (cfDNA) carrying gene expression information of the original tiss...

    Authors: Xu Yang, Qing Liu, Zhiwei Guo, Xuexi Yang, Kun Li, Bowei Han, Min Zhang, Minying Sun, Limin Huang, Gengxi Cai and Yingsong Wu
    Citation: Breast Cancer Research 2024 26:112
    Content type: Research Published on:

  19. Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The androgen receptor (AR) is also expressed in the vast majority (80–90...

    Authors: Huanyao Gao, Lixuan Wei, Shreya Indulkar, Thanh Thanh. L. Nguyen, Duan Liu, Ming-Fen Ho, Cheng Zhang, Hu Li, Richard M. Weinshilboum, James N. Ingle and Liewei Wang
    Citation: Breast Cancer Research 2024 26:111
    Content type: Research Published on:

  20. Breast cancer (BC) is a highly prevalent malignancy worldwide, with complex pathogenesis and treatment challenges. Research reveals that methyltransferase-like 3 (METTL3) is widely involved in the pathogenesis...

    Authors: Dongqiong Xiao, Mingfu Zhang, Yi Qu and Xiaojuan Su
    Citation: Breast Cancer Research 2024 26:110
    Content type: Review Published on:

  21. The effect of gender-affirming testosterone therapy (TT) on breast cancer risk is unclear. This study investigated the association between TT and breast tissue composition and breast tissue density in trans ma...

    Authors: Yujing J. Heng, Gabrielle M. Baker, Valerie J. Fein-Zachary, Yaileen D. Guzman-Arocho, Vanessa C. Bret-Mounet, Erica S. Massicott, Vanda F. Torous, Stuart J. Schnitt, Sy Gitin, Paul Russo, Adam M. Tobias, Richard A. Bartlett, Gopal Varma, Despina Kontos, Lusine Yaghjyan, Michael S. Irwig…
    Citation: Breast Cancer Research 2024 26:109
    Content type: Research Published on:

  22. Metastasis, the spread, and growth of malignant cells at secondary sites within a patient’s body, accounts for over 90% of cancer-related mortality. Breast cancer is the most common tumor type diagnosed and th...

    Authors: Chenran Wang, Aarti Nagayach, Harsh Patel, Lan Dao, Hui Zhu, Amanda R. Wasylishen, Yanbo Fan, Ady Kendler and Ziyuan Guo
    Citation: Breast Cancer Research 2024 26:108
    Content type: Research Published on:

  23. HER3, a member of the EGFR receptor family, plays a central role in driving oncogenic cell proliferation in breast cancer. Novel HER3 therapeutics are showing promising results while recently developed HER3 PE...

    Authors: Nicoleta Sinevici, Christine E. Edmonds, Brian N. Dontchos, Gary Wang, Constance D. Lehman, Steven Isakoff and Umar Mahmood
    Citation: Breast Cancer Research 2024 26:107
    Content type: Research Published on:

  24. The cell cycle of mammary stem cells must be tightly regulated to ensure normal homeostasis of the mammary gland to prevent abnormal proliferation and susceptibility to tumorigenesis. The atypical cell cycle r...

    Authors: Bre-Anne Fifield, John Vusich, Erika Haberfellner, Eran R. Andrechek and Lisa A. Porter
    Citation: Breast Cancer Research 2024 26:106
    Content type: Research Published on:

  25. Circular RNAs (circRNAs) are a new group of endogenous RNAs recently found to be involved in the development of various diseases, including their confirmed involvement in the progression of several types of ca...

    Authors: Dandan Wang, Sujin Yang, Mengmeng Lyu, Liping Xu, Shanliang Zhong and Dandan Yu
    Citation: Breast Cancer Research 2024 26:105
    Content type: Research Published on:

  26. Immune-positron emission tomography (PET) imaging with tracers that target CD8 and granzyme B has shown promise in predicting the therapeutic response following immune checkpoint blockade (ICB) in immunologica...

    Authors: Yun Lu, Hailey A. Houson, Carlos A. Gallegos, Alessandro Mascioni, Fang Jia, Argin Aivazian, Patrick N. Song, Shannon E. Lynch, Tiara S. Napier, Ameer Mansur, Benjamin M. Larimer, Suzanne E. Lapi, Ariella B. Hanker and Anna G. Sorace
    Citation: Breast Cancer Research 2024 26:104
    Content type: Research Published on:

  27. Triple-negative breast cancer (TNBC) represents a highly aggressive subset of breast malignancies characterized by its challenging clinical management and unfavorable prognosis. While TFAP2A, a member of the A...

    Authors: Yujie Fang, Yali Wang, Hongning Ma, Yuqi Guo, Rongrong Xu, Xixi Chen, Xuehua Chen, Ye Lv, Pu Li and Yujing Gao
    Citation: Breast Cancer Research 2024 26:103
    Content type: Research Published on:

  28. Early menarche is an established risk factor for breast cancer but its molecular contribution to tumor biology and prognosis remains unclear.

    Authors: Alexandra R. Harris, Tengteng Wang, Yujing J. Heng, Gabrielle M. Baker, Phuong Anh Le, Jun Wang, Christine Ambrosone, Adam Brufsky, Fergus J. Couch, Francesmary Modugno, Christopher G. Scott, Celine M. Vachon, Susan E. Hankinson, Bernard A. Rosner, Rulla M. Tamimi, Cheng Peng…
    Citation: Breast Cancer Research 2024 26:102
    Content type: Research Published on:

  29. Little is known about how use of chemotherapy has evolved in breast cancer patients. We therefore describe chemotherapy patterns for women with stage I-IIIA breast cancer in the Optimal Breast Cancer Chemother...

    Authors: Jenna Bhimani, Kelli O’Connell, Isaac J. Ergas, Marilyn Foley, Grace B. Gallagher, Jennifer J. Griggs, Narre Heon, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H. Kroenke, Cecile. A. Laurent, Raymond Liu, Kanichi G. Nakata, Sonia Persaud, Donna R. Rivera, Janise M. Roh…
    Citation: Breast Cancer Research 2024 26:101
    Content type: Brief Report Published on:

  30. Immunohistochemistry (IHC) and in situ hybridization (ISH) remain standard biomarkers for therapeutic decisions in human epidermal growth factor 2 (HER2)-positive breast cancers (BCs); however, they are insuff...

    Authors: Huang-Chun Lien, Chiao Lo, Yi-Hsuang Lee, Po-Hang Lin, Ming-Yang Wang, Wen-Hung Kuo, Li-Wei Tsai, Yen-Shen Lu, Hsiang-Wei Hu, Yu-Chia Li and Chiun-Sheng Huang
    Citation: Breast Cancer Research 2024 26:100
    Content type: Research Published on:

  31. In this study, we prepared a bionic nanosystem of trastuzumab-functionalized SK-BR-3 cell membrane hybrid liposome-coated pyrotinib (Ptb-M-Lip-Her) for the treatment of HER2-positive breast cancer. Transmissio...

    Authors: Jiaqun Du, Xiaobang Liu, Junpeng Sun, Qian Wu, Yu Hu, Huan Shi, Li Zheng, Ying Liu, Chao Wu and Yu Gao
    Citation: Breast Cancer Research 2024 26:99
    Content type: Research Published on:

  33. Tumor immune infiltration and peripheral blood immune signatures have prognostic and predictive value in breast cancer. Whether distinct peripheral blood immune phenotypes are associated with response to neoad...

    Authors: Roberto A. Leon-Ferre, Kaitlyn R. Whitaker, Vera J. Suman, Tanya Hoskin, Karthik V. Giridhar, Raymond M. Moore, Ahmad Al-Jarrad, Sarah A. McLaughlin, Donald W. Northfelt, Katie N. Hunt, Amy Lynn Conners, Ann Moyer, Jodi M. Carter, Krishna Kalari, Richard Weinshilboum, Liewei Wang…
    Citation: Breast Cancer Research 2024 26:97
    Content type: Research Published on:

  34. Metabolic plasticity mediates breast cancer survival, growth, and immune evasion during metastasis. However, how tumor cell metabolism is influenced by and feeds back to regulate breast cancer progression are ...

    Authors: Michael F. Coleman, Eylem Kulkoyluoglu Cotul, Alexander J. Pfeil, Emily N. Devericks, Muhammad H. Safdar, Marvis Monteiro, Hao Chen, Alyssa N. Ho, Numair Attaar, Hannah M. Malian, Violet A. Kiesel, Alexis Ramos, Matthew Smith, Heena Panchal, Adam Mailloux, Dorothy Teegarden…
    Citation: Breast Cancer Research 2024 26:96
    Content type: Research Published on:

  35. Breast cancers treated with aromatase inhibitors (AIs) can develop AI resistance, which is often driven by estrogen receptor-alpha (ERα/ESR1) activating mutations, as well as by ER-independent signaling pathways....

    Authors: Muriel Lainé, Marianne E Greene, Justyna D Kurleto, Grazyna Bozek, Tiffany Leng, Rosemary J Huggins, Barry S Komm and Geoffrey L Greene
    Citation: Breast Cancer Research 2024 26:95
    Content type: Research Published on:

  36. RNA m5C methylation has been extensively implicated in the occurrence and development of tumors. As the main methyltransferase, NSUN2 plays a crucial regulatory role across diverse tumor types. However, the preci...

    Authors: Xuran Zhang, Ke An, Xin Ge, Yuanyuan Sun, Jingyao Wei, Weihong Ren, Han Wang, Yueqin Wang, Yue Du, Lulu He, Ouwen Li, Shaoxuan Zhou, Yong Shi, Tong Ren, Yun-gui Yang, Quancheng Kan…
    Citation: Breast Cancer Research 2024 26:94
    Content type: Research Published on:

  37. Inflammation could be related to cancer-related cognitive impairment (CRCI) and might be used as a predictive marker of long-term CRCI. We evaluated associations between inflammatory markers assessed at diagno...

    Authors: Mylène Duivon, Justine Lequesne, Antonio Di Meglio, Caroline Pradon, Ines Vaz-Luis, Anne-Laure Martin, Sibille Everhard, Sophie Broutin, Olivier Rigal, Chayma Bousrih, Christelle Lévy, Florence Lerebours, Marie Lange and Florence Joly
    Citation: Breast Cancer Research 2024 26:93
    Content type: Research Published on:

  38. Identifying new targets in triple negative breast cancer (TNBC) remains critical. REG3A (regenerating islet-derived protein 3 A), a calcium-dependent lectin protein, was thoroughly investigated for its express...

    Authors: Xiaoxia Jin, Shuyun Yang, Xiaoyun Lu, Xudong Chen and Wencheng Dai
    Citation: Breast Cancer Research 2024 26:92
    Content type: Research Published on:

  39. The aberrant amplification of mammary luminal progenitors is at the origin of basal-like breast cancers associated with BRCA1 mutations. Integrins mediate cell–matrix adhesion and transmit mechanical and chemi...

    Authors: Marisa M. Faraldo, Mathilde Romagnoli, Loane Wallon, Pierre Dubus, Marie-Ange Deugnier and Silvia Fre
    Citation: Breast Cancer Research 2024 26:91
    Content type: Research Published on:

  40. Nottingham histological grade (NHG) is a well established prognostic factor in breast cancer histopathology but has a high inter-assessor variability with many tumours being classified as intermediate grade, N...

    Authors: Constance Boissin, Yinxi Wang, Abhinav Sharma, Philippe Weitz, Emelie Karlsson, Stephanie Robertson, Johan Hartman and Mattias Rantalainen
    Citation: Breast Cancer Research 2024 26:90
    Content type: Research Published on:

  41. Early-stage invasive ductal carcinoma displays high survival rates due to early detection and treatments. However, there is still a chance of relapse of 3–15% after treatment. The aim of this study was to unco...

    Authors: Pere Miquel Morla-Barcelo, David Laguna-Macarrilla, Octavi Cordoba, Gabriel Matheu, Jordi Oliver, Pilar Roca, Mercedes Nadal-Serrano and Jorge Sastre-Serra
    Citation: Breast Cancer Research 2024 26:89
    Content type: Research Published on:

  42. Associations between reproductive factors and risk of breast cancer differ by subtype defined by joint estrogen receptor (ER), progesterone receptor (PR), and HER2 expression status. Racial and ethnic differen...

    Authors: Esther M. John, Jocelyn Koo, Amanda I. Phipps, Teri A. Longacre, Allison W. Kurian, Sue A. Ingles, Anna H. Wu and Lisa M. Hines
    Citation: Breast Cancer Research 2024 26:88
    Content type: Research Published on:

  43. Despite progress understanding the mechanisms underlying tumor spread, metastasis remains a clinical challenge. We identified the choline-producing glycerophosphodiesterase, EDI3 and reported its association w...

    Authors: Annika Glotzbach, Katharina Rohlf, Anastasia Gonscharow, Simon Lüke, Özlem Demirci, Brigitte Begher-Tibbe, Nina Overbeck, Jörg Reinders, Cristina Cadenas, Jan G. Hengstler, Karolina Edlund and Rosemarie Marchan
    Citation: Breast Cancer Research 2024 26:87
    Content type: Research Published on:

  44. Copy number gains in genes coding for Rho activating exchange factors as well as losses affecting genes coding for RhoGAP proteins are common in breast cancer (BC), suggesting that elevated Rho signaling may p...

    Authors: Nandini Raghuram, E. Idil Temel, Toshihiro Kawamata, Katelyn J. Kozma, Amanda J. Loch, Wei Wang, Jessica R. Adams, William J. Muller and Sean E. Egan
    Citation: Breast Cancer Research 2024 26:86
    Content type: Research Published on:

  45. Abbreviated breast MRI (FAST MRI) is being introduced into clinical practice to screen women with mammographically dense breasts or with a personal history of breast cancer. This study aimed to optimise diagno...

    Authors: Lyn I. Jones, Andrea Marshall, Rebecca Geach, Premkumar Elangovan, Elizabeth O’Flynn, Tony Timlin, Sadie McKeown-Keegan, Janice Rose, Sarah Vinnicombe, Sian Taylor-Phillips, Mark Halling-Brown and Janet A. Dunn
    Citation: Breast Cancer Research 2024 26:85
    Content type: Research Published on:

  47. Authors: Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra…
    Citation: Breast Cancer Research 2024 26:83
    Content type: Correction Published on:

    The original article was published in Breast Cancer Research 2024 26:69

  48. Patients with a Breast Imaging Reporting and Data System (BI-RADS) 4 mammogram are currently recommended for biopsy. However, 70–80% of the biopsies are negative/benign. In this study, we developed a deep lear...

    Authors: Chang Liu, Min Sun, Dooman Arefan, Margarita Zuley, Jules Sumkin and Shandong Wu
    Citation: Breast Cancer Research 2024 26:82
    Content type: Research Published on:

  49. The proportion of patients with breast cancer and obesity is increasing. While the therapeutic landscape of breast cancer has been expanding, we lack knowledge about the potential differential efficacy of most...

    Authors: Josephine Van Cauwenberge, Karen Van Baelen, Marion Maetens, Tatjana Geukens, Ha Linh Nguyen, Ines Nevelsteen, Ann Smeets, Anne Deblander, Patrick Neven, Stijn Koolen, Hans Wildiers, Kevin Punie and Christine Desmedt
    Citation: Breast Cancer Research 2024 26:81
    Content type: Review Published on:

  50. Cancer-related fatigue (CRF) is a pervasive, persistent, and distressing symptom experienced by cancer patients, for which few treatments are available. We investigated the efficacy and safety of infrared lase...

    Authors: Huijuan Mao, Ming Jin, Lulu Xie, Ni Mao, Xubo Shen, Junchao Chen, Xuefen Chen, Jun J. Mao and Xueyong Shen
    Citation: Breast Cancer Research 2024 26:80
    Content type: Research Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 6.1
    5-year Journal Impact Factor: 7.1
    Source Normalized Impact per Paper (SNIP): 1.865
    SCImago Journal Rank (SJR): 2.578

    Speed 2023
    Submission to first editorial decision (median days): 14
    Submission to acceptance (median days): 129

    Usage 2023
    Downloads: 2,432,781
    Altmetric mentions: 1,561

Breast Cancer Research

ISSN: 1465-542X

Contact us